07-12-2025 22:18 via medpagetoday.com

Chemotherapy-Free Triplet 'Sets a New Benchmark' in Follicular Lymphoma

(MedPage Today) -- ORLANDO--Adding the bispecific antibody epcoritamab (Epkinly) to a standard chemotherapy-free regimen for relapsed or refractory follicular lymphoma improved responses and reduced the risk of disease progression or death...
Read more »

Medical news



Adding Procedures, Cutting the Paperwork
CDC Panel Targets Size of Childhood Vaccine Schedule, Safety of Aluminum Adjuvants
Experts Evaluate Aging and Hematologic Disease at ASH
IV Iron Tied to Lower Mortality Risk in Anemics Battling Infection
Fellow Nurses: Hep B Vaccine Recommendation for Newborns Was Dropped
Stabbed Hospital Worker Dies; ACA Battle Intensifies; Killer Mushroom Outbreak
'This Would Be a Hugely Important Finding': What We Heard This Week
Alzheimer's Benefits May Continue After Donanemab Treatment Ends, Data Suggest
Potential Game-Changing Impact on Mismatched Unrelated Blood Cell Transplantation
TBI-Free Conditioning Before Transplant Effective in MRD-Negative B-ALL
The Internet's Risky Pseudo-Cures
Want Good Info on Epilepsy Treatment? Don't Ask Dr. TikTok
Fixed-Duration or Continuous Therapy in CLL: Trial Says Take Your Pick
What Did Trump's MRI Assess?
Desktop versie